secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001819790-26-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus reports FY2025 XDEMVY sales of $451.4M (+150% YoY); net loss narrows to $66.4M; guides peak >$2B
--------------------------------------------------------------------------------

- Q4 2025 net product sales $151.7M (Q4 2024: $66.4M); full-year $451.4M; ~400,000 bottles delivered in 2025.
- Full-year net loss $66.4M ($1.59 loss per share) vs $115.6M ($3.07) in 2024; Q4 net loss $8.4M ($0.20) vs $23.1M ($0.60).
- Management guided XDEMVY peak sales potential >$2B; gross margin held at 93%; cash $417.3M at year-end.
- Initiated Phase 2 trial of TP-04 for ocular rosacea (topline 1H 2027); TP-05 Phase 2 for Lyme prevention expected Q2 2026.
- David E.I. Pyott (former Allergan CEO) appointed to board; DTC campaign boosted patient awareness of Demodex blepharitis to ~25%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000017/0001819790-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000017/tars-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001819790-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer